TP53 and acute myeloid leukemia: By contrast, mice injected with MOLM13-TP53+/+ AML cells and treated with anti-CD33 CAR T-cells showed decreased leukemic burden, and significantly prolonged survival for up to 10 weeks (Figs. 3B–D and EV2).